Agendia and CBLPath Announce Agreement to Assist Physicians in Diagnostic Assessment of Breast Cancer

Publication Name: Press Release

IRVINE, CA, AMSTERDAM and Rye Brook, N.Y., July 16, 2014 – Agendia, a leading molecular diagnostics company, and CBLPath, Inc., a leading pathology services provider, today announced they have agreed to collaborate in providing molecular diagnostics testing to breast cancer patients.

“We expect this collaboration to have a significant clinical impact,” said Neil Barth, M.D., Agendia’s Chief Medical Officer. “A large part of CBLPath’s focus is on breast cancer. Agendia’s MammaPrint test is a sophisticated assay for breast cancer recurrence risk. Through our BluePrint assay, we also provide a widely available test for molecular subtyping of breast cancer. By working more closely together, Agendia and CBLPath will move the treatment of breast cancer toward better outcomes and fewer unnecessary side-effects.”

The collaboration is expected to advance the availability of personalized medicine and to benefit both physicians who treat breast cancer and women who have the disease.

“Pathologists’ approach to breast cancer diagnosis is being significantly advanced by molecular diagnostics,” said Carlos D. Urmacher, M.D., FCAP, FASCP, Co-Chief Executive Officer and Chief Medical Officer of CBLPath. “CBLPath’s expertise in breast pathology coupled with Agendia’s innovative tests will provide definitive information for breast cancer patients and their physicians when evaluating treatment options. Given the prominence of CBLPath and Agendia in providing sophisticated laboratory services in this field, I look forward to a powerfully synergistic relationship between the two companies.”

About Agendia

Agendia is a leading molecular diagnostics company that develops and markets FFPE-based genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia’s tests were developed using an unbiased gene selection by analyzing the complete human genome. This includes MammaPrint as well as BluePrint, a molecular subtyping assay that provides deeper insight leading to more clinically actionable biology. MammaPrint is the only breast cancer recurrence assay backed by peer-reviewed, prospective outcome data. These tests can help physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal, or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.

In addition, Agendia has a pipeline of other genomic products in development. The company collaborates with other companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and the MINDACT trials. For more information, visit www.agendia.com.

About CBLPath

CBLPath, a Sonic Healthcare USA laboratory, is a leading pathology services provider, combining anatomic pathology with advanced molecular diagnostics, esoteric testing, and digital pathology. CBLPath is committed to helping our clients deliver better medicine, faster. At our core are pathologists dedicated to utilizing and integrating comprehensive diagnostic, prognostic, and theranostic testing designed to deliver personalized medicine and to provide our subspecialty physician clients timely, accurate results enabling the most effective patient care. For more about the company, please visit CBLPath.com.

Contact:

Liz Dowling (Medical & Consumer Media)
Dowling & Dennis Public Relations
415-388-2794
Liz@DowlingDennis.net

Matt Clawson (Financial Media)
Pure Communications
949-370-8500
Matt@purecommunications.com

Carlos Urmacher, M.D.
Co-CEO & CMO
CBLPath
914-698-5706

Tom Curtis
SVP, Marketing
Sonic Healthcare USA
240-566-2884